https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46788 Wed 30 Nov 2022 13:21:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45277 0.14). Conclusion: In this secondary analysis of a primary efficacy study, PD was a common comorbidity among those with MDD, but was not a significant predictor of functional outcomes. This study adds to the limited literature on PD in randomized controlled trials for MDD.]]> Wed 26 Oct 2022 17:13:15 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36597 Wed 10 Jun 2020 15:12:41 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36280 Thu 19 Mar 2020 17:51:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26171 Sat 24 Mar 2018 07:30:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39177 n = 133). Participants received 16 weeks adjunctive treatment of either placebo or N-acetylcysteine-alone or a combination of mitochondrial-enhancing nutraceuticals including N-acetylcysteine (combination treatment). Participants were followed up 4 weeks post-treatment discontinuation (Week 20). Diet was assessed by the Cancer Council Victoria Dietary Questionnaire for Epidemiological Studies, Version 2, converted into an Australian Recommended Food Score to measure diet quality, and energy-adjusted dietary inflammatory index score to measure inflammatory potential of diet. Body mass index was also measured. Generalised estimating equation models were used to assess whether diet quality, energy-adjusted dietary inflammatory index score and/or body mass index were predictors of response to significant outcomes of the primary trial: depression symptoms, clinician-rated improvement and functioning measures. Results: In participants taking combination treatment compared to placebo, change in depression scores was not predicted by Australian Recommended Food Score, dietary inflammatory index or body mass index scores. However, participants with better diet quality (Australian Recommended Food Score) reported reduced general depression and bipolar depression symptoms (p = 0.01 and p = 0.03, respectively) and greater clinician-rated improvement (p = 0.02) irrespective of treatment and time. Participants who had a more anti-inflammatory dietary inflammatory index had less impairment in functioning (p = 0.01). Combination treatment may attenuate the adverse effects of pro-inflammatory diet (p = 0.03) on functioning. Participants with lower body mass index who received combination treatment (p = 0.02) or N-acetylcysteine (p = 0.02) showed greater clinician-rated improvement. Conclusion: These data support a possible association between diet (quality and inflammatory potential), body mass index and response to treatment for bipolar depression in the context of a nutraceutical trial. The results should be interpreted cautiously because of limitations, including numerous null findings, modest sample size and being secondary analyses.]]> Mon 23 May 2022 14:53:36 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47591 Mon 23 Jan 2023 14:49:38 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52335 Mon 09 Oct 2023 14:50:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51700 Fri 15 Sep 2023 10:39:15 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51362 Fri 01 Sep 2023 13:44:30 AEST ]]>